Americafirst Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Americafirst Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$702K	Buy	+7,548	New	+$667K	0.95%	21

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Americafirst Capital Management's BMRN Position: Q3 2017 in Review

Americafirst Capital Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2017: 7,548 shares worth $702K. The stake represents 0.95% of the portfolio and ranks #21 among its holdings.

411 funds tracked by Wall St. Rank hold BMRN as of Q3 2017.

Americafirst Capital Management held 7,548 shares of BioMarin Pharmaceuticals worth $702K as of Q3 2017.
BioMarin Pharmaceuticals was a new Americafirst Capital Management position in Q3 2017.
BioMarin Pharmaceuticals made up 0.95% of Americafirst Capital Management's portfolio in Q3 2017, its #21 holding.
411 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2017.

Based on Americafirst Capital Management's 13F filing for Q3 2017, filed 16 Nov 2017.